Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs AZITHROMYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting m RNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Acute bacterial exacerbations of chronic obstructive pulmonary disease due to H. influenzae, M. catarrhalis, or S. pneumoniae,Acute bacterial sinusitis due to H. influenzae, M. catarrhalis, or S. pneumoniae,Community-acquired pneumonia due to C. pneumoniae, H. influenzae, M. pneumoniae, or S. pneumoniae,Pharyngitis/tonsillitis due to S. pyogenes,Uncomplicated skin and skin structure infections due to S. aureus, S. pyogenes, or S. agalactiae,Urethritis/cervicitis due to C. trachomatis or N. gonorrhoeae,Genital ulcer disease due to H. ducreyi,Acute otitis media due to H. influenzae, M. catarrhalis, or S. pneumoniae,Prevention of disseminated M. avium complex disease in advanced HIV infection,Pertussis (off-label)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal half-life of approximately 68 hours (range 35–96 h) after multiple doses, allowing once-daily dosing and a prolonged post-antibiotic effect.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily hepatic, not via cytochrome P450 system. Partially metabolized to inactive metabolites. Eliminated via biliary excretion and renal excretion (<15% unchanged).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Primarily biliary/fecal (approx. 50% unchanged); renal excretion accounts for about 12% of the dose.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
7–51% (concentration-dependent); primarily binds to albumin.
4-6 L/kg; large Vd indicates extensive tissue distribution
31.1 L/kg (range 23–50 L/kg), indicating extensive tissue penetration and sequestration (e.g., WBCs, liver, lung).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: 37–40% (fasting); food may decrease absorption by ~50%.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required for GFR ≥10 m L/min. For GFR <10 m L/min, caution advised; no specific dose recommendation, consider alternative agent.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A and B). Contraindicated in severe hepatic impairment (Child-Pugh class C).
Not approved for pediatric patients <18 years; safety and efficacy not established.
For otitis media and community-acquired pneumonia: 10 mg/kg orally or IV on day 1 (max 500 mg), then 5 mg/kg (max 250 mg) once daily on days 2-5. For pharyngitis/tonsillitis: 12 mg/kg orally once daily for 5 days (max 500 mg/day).
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific dose adjustment required; use same dosing as younger adults. Monitor renal function due to age-related decline, but no modification needed unless severe renal impairment (Cr Cl <10 m L/min).
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hepatotoxicity: hepatitis, cholestatic jaundice, hepatic necrosis, hepatic failure,QT prolongation and torsades de pointes (especially with concurrent use of other QT-prolonging agents, electrolyte abnormalities, bradycardia, or structural heart disease),Clostridioides difficile-associated diarrhea (CDAD),Aggravation of myasthenia gravis,Severe allergic reactions (angioedema, anaphylaxis, Stevens-Johnson syndrome),Infantile hypertrophic pyloric stenosis (IHPS) in neonates following oral azithromycin,Use in pregnancy: category B; avoid during breastfeeding due to potential for disruption of infant gut flora
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,History of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use,Concurrent use with ergotamine or dihydroergotamine (possible ergot toxicity)
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Food does not significantly affect absorption; can be taken with or without food. However, avoiding high-fat meals may reduce minor GI side effects. No known specific food interactions.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
FDA Category B. No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No significant association with birth defects. Second/third trimester: No reported fetal harm from short-term use for infections like chorioamnionitis. Use only if clearly needed.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Azithromycin is excreted into breast milk in low amounts. M/P ratio approximately 0.2-0.6. Relative infant dose estimated at 2-6% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding; monitor infant for diarrhea or rash.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No dose adjustment required for pregnancy. Standard adult dosing (500 mg on day 1, then 250 mg daily for 4 days) is appropriate. Note: Pregnancy may increase volume of distribution, but pharmacokinetic studies suggest no significant decrease in AUC; no need for dose increase.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Monitor for QTc prolongation especially in patients with preexisting cardiac conditions or those on other QT-prolonging drugs. Azithromycin has a long half-life (68 hours) allowing for shorter treatment courses. Use with caution in hepatic impairment; consider alternative in severe liver disease. Not recommended for pneumonia in patients with bacteremia due to increased mortality risk. Administer on an empty stomach or with food if GI upset occurs; however, absorption is unaffected by food.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take exactly as prescribed; do not skip doses or stop early even if you feel better.,Do not take antacids containing aluminum or magnesium within 2 hours before or after this medication.,Report any signs of liver problems (nausea, vomiting, dark urine, jaundice) or severe diarrhea (watery or bloody) immediately.,Azithromycin may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Inform your doctor if you have a history of QT prolongation, heart rhythm problems, or electrolyte imbalances.,Store at room temperature away from moisture and heat; discard any unused liquid after 10 days.
No interactions on record
"Azithromycin, a macrolide antibiotic, is known to prolong the QT interval by blocking cardiac potassium channels (specifically IKr), which can lead to torsades de pointes. Mifepristone also poses a risk of QT prolongation, likely via similar mechanisms. Coadministration may result in additive QTc prolongation, increasing the risk of life-threatening ventricular arrhythmias, especially in patients with preexisting cardiac conditions or electrolyte disturbances."
"Lumiracoxib is a selective COX-2 inhibitor primarily metabolized by CYP2C9 and to a lesser extent by CYP3A4. Azithromycin, a macrolide antibiotic, is a known inhibitor of CYP3A4. Concomitant use may decrease the metabolism of azithromycin, leading to increased plasma concentrations and potential toxicity, such as QT prolongation and hepatotoxicity. Elevated azithromycin levels can also enhance its antibacterial effects but raise safety concerns."
"Azithromycin, a macrolide antibiotic, inhibits the cardiac potassium channel encoded by hERG (human Ether-à-go-go-Related Gene), leading to prolonged cardiac repolarization and increased risk of QTc interval prolongation. Arformoterol, a long-acting beta-2 agonist, can also prolong the QTc interval via beta-adrenergic receptor-mediated effects on cardiac ion channels. Concurrent use may result in additive QTc prolongation, predisposing patients to potentially fatal ventricular arrhythmias such as torsades de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs AZITHROMYCIN, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. AZITHROMYCIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting m RNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and AZITHROMYCIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of AZITHROMYCIN is: 500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and AZITHROMYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. AZITHROMYCIN is classified as Category A/B. FDA Category B. No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No significant association with . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.